recombinant mouse fstl1 proteins (R&D Systems)
Structured Review

Recombinant Mouse Fstl1 Proteins, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse fstl1 proteins/product/R&D Systems
Average 93 stars, based on 11 article reviews
Images
1) Product Images from "FSTL1 Suppresses Triple-Negative Breast Cancer Lung Metastasis by Inhibiting M2-like Tumor-Associated Macrophage Recruitment toward the Lungs"
Article Title: FSTL1 Suppresses Triple-Negative Breast Cancer Lung Metastasis by Inhibiting M2-like Tumor-Associated Macrophage Recruitment toward the Lungs
Journal: Diagnostics
doi: 10.3390/diagnostics13101724
Figure Legend Snippet: Lower FSTL1 expression in breast cancer tissues compared to normal breast tissues, and high expression of FSTL1 meant prolonged survival. ( A – D ) FSTL1 mRNA expression decreased in primary breast cancer. ( E , F ) FSTL1 had no significant effect on the survival rate of patients with breast invasive carcinoma (BRCA) and TNBC. ( G , H ) High FSTL1 expression could increase the survival rate of patients with breast cancer and those with positive nodal metastasis. *** p < 0.001.
Techniques Used: Expressing
Figure Legend Snippet: FSTL1 had no effect on the proliferation and EMT markers of 4T1 cells. ( A ) The proliferation ability of 4T1 TNBC cells showed no change after 600 ng/mL FSTL1 treatment for 1–4 d. ( B ) Under different FSTL1 concentration treatments, expression of 4T1 EMT markers, including E-cadherin and N-cadherin, showed no change after 12 h treatment.
Techniques Used: Concentration Assay, Expressing
Figure Legend Snippet: Total and M2 macrophage ratios increased in breast cancer lung metastasis in Fstl1 +/− mice. ( A , B ) Total (F4/80+) and M2 (F4/80+CD11c-CD206+) macrophage ratios in WT and Fstl1 +/− mice on the 0th and 28th day. ( C – E ) Expression of several M2-related macrophage markers (IL4, IL13, Arg-1, and IL10) in WT and Fstl1 +/− mice on the 0th and 28th day. ( F , G ) Western blot of metastasis-related markers (TGFβ and MMP9) of WT and Fstl1 +/− mice on the 28th day. * p < 0.05, ** p < 0.01, *** p < 0.001.
Techniques Used: Expressing, Western Blot
Figure Legend Snippet: FSTL1 inhibited macrophage migration toward 4T1 breast cancer cells. ( A , B , D , E ) RAW264.7/Ana-1 (the upper transwell) and 4T1 cells (the lower transwell), stimulator: FSTL1 (1 μg/mL) ± IL4 (20 ng/mL), transmembrane macrophage morphology was observed, and numbers (5 fields per slide) were calculated after 12 h co-culture. ( C , F ) Migrated RAW264.7/Ana-1 macrophages toward 4T1 breast cancer cells decreased in FSTL1 (1 μg/mL) treatment group. * p < 0.05, ** p < 0.01, *** p < 0.001.
Techniques Used: Migration, Co-Culture Assay
Figure Legend Snippet: Recombinant mouse FSTL1 protein inhibited several cytokines produced by 4T1 TNBC cells. ( A ) FSTL1 (1 μg/mL)-treated 4T1 cells with or without IL4 (20 ng/mL) in vitro. Cytokine secretions: ( B ) CCL2, ( C ) CCL5, ( D ) CSF1, ( E ) VEGF-α, and ( F ) TGF-β. ( G ) Schematic representation of the effect of FSTL1 on breast cancer metastatic tumor growth. The model depicts the suppression of CSF1, VEGF-α, and TGF-β secretion in 4T1 breast cancer cells by FSTL1, which decreases macrophage recruitment toward TNBC cells. * p < 0.05, ** p < 0.01, *** p < 0.001.
Techniques Used: Recombinant, Produced, In Vitro


